logo-loader
CelLBxHealth PLC

Angle PLC - Board Changes

RNS Number : 0495Z
Angle PLC
12 September 2025
 

For immediate release

12 September 2025

 

ANGLE plc ("the Company")

 

BOARD CHANGES 

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that, following feedback and discussions with a significant shareholder, Andrew Newland, Chief Executive, and Ian Griffiths, Finance Director, have agreed to step down from their positions on the Board.

 

They remain committed and supportive of the Company and intend to support the Company with an orderly handover.

 

The Board now comprises Dr. Jan Groen, Non-executive Chairman, and Dr. Joseph Eid, Non-executive Director.  It is proposed that the Board be expanded in due course.

 

 

For further information:

 

ANGLE plc

+44 (0) 1483 343434

Dr. Jan Groen, Non-executive Chairman

Dr. Joseph Eid, Non-executive Director

j.groen@angleplc.com

 

 

Cavendish (NOMAD and Broker)

Geoff Nash / Isaac Hooper (Corporate Finance)

Sunila de Silva (Corporate Broking)

Nigel Birks (Life Science Specialist Sales)

 

+44 (0) 20 7220 0500

 

FTI Consulting

Simon Conway, Ciara Martin, Sam Purewal

Matthew Ventimiglia (US)

 

 

+44 (0) 203 727 1000

+1 (212) 850 5624

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories.  Services include custom made assay development and clinical trial testing for pharma.

 

Over 115 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPKDBQDBKBCCD
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

Gelion, CelLBxHealth, Ashtead Technology, Rainbow Rare Earths, Bradda Head...

Gelion PLC (AIM:GELN, OTC:GELNF) shares rose over 12% to 18p after it reported £9.6 million of pro forma cash and no debt. Releasing full-year results, it noted agreements with two major automakers, and the CEO says it’s moving from validation towards customer programmes and scale-up. Read...

4 weeks, 1 day ago

3 min read